SAN FRANCISCO--(BUSINESS WIRE)--Meliora Therapeutics (“Meliora”), a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter Weinand, former Chairman and CEO of Bayer Pharmaceuticals, as Meliora’s Chairman of the Board, and the appointment of Jean-Jacques Bienaimé, former Chairman and CEO of BioMarin, to Meliora’s Board of Directors as Independent Director..

旧金山--（商业新闻短讯）--开发新型和变革性癌症药物的机器学习治疗公司Meliora Therapeutics（“Meliora”）今天宣布任命拜耳制药前董事长兼首席执行官Dieter Weinand为Meliora董事会主席，任命BioMarin前董事长兼首席执行官Jean-Jacques Bienaimé为Meliora董事会独立董事。。

“We are thrilled to have Dieter Weinand and Jean-Jacques Bienaimé join Meliora’s Board of Directors,” stated David Li, Meliora co-founder and Chief Executive Officer. “Their expertise and leadership in drug development will be incredible assets to our company. I look forward to working closely with both to further Meliora’s vision of being the world’s leading machine learning oncology therapeutics company.”.

“我们很高兴DieterWeinand和Jean-Jacques Bienaimé加入梅利奥拉的董事会，”梅利奥拉联合创始人兼首席执行官David Li表示。“他们在药物开发方面的专业知识和领导才能将是我们公司难以置信的资产。我期待着与他们密切合作，以进一步推动Meliora成为世界领先的机器学习肿瘤治疗公司的愿景。”。

Dieter Weinand is an experienced business leader with over 30 years of experience in the pharmaceutical industry and the former CEO and Chairman of the Board of Bayer Pharmaceuticals. During a career stretching back over 30 years, he has held various responsibilities in general management, commercial, operational and strategic leadership roles, leading business operations in the Asia-Pacific region, Europe, the Middle East, Africa, Latin America and the United States, for companies including Bayer, Pfizer, Bristol-Myers Squibb, and Sanofi..

迪特尔·韦南德（DieterWeinand）是一位经验丰富的商业领袖，在制药行业拥有30多年的经验，曾任拜耳制药（Bayer Pharmaceuticals）首席执行官兼董事会主席。在30多年的职业生涯中，他曾在拜耳（Bayer）、辉瑞（Pfizer）、百时美施贵宝（Bristol-Myers Squibb）和赛诺菲（Sanofi）等公司担任综合管理、商业、运营和战略领导职务，领导亚太地区、欧洲、中东、非洲、拉丁美洲和美国的业务运营。。

He has also led the development, launch, and commercialization of products in various therapeutic areas, including cardiovascular diseases, oncology, dermatology, immunology, and respiratory and inflammatory diseases. He is currently Chairman of the Board of Replimune (REPL), Umoja, and Inspirna, and Executive Chairman of the Board of Mnemo Therapeutics.

他还领导了各种治疗领域产品的开发，推出和商业化，包括心血管疾病，肿瘤学，皮肤病，免疫学以及呼吸和炎症疾病。他目前是Replimune（REPL），Umoja和Inspirna董事会主席，以及Mnemo Therapeutics董事会执行主席。

He earned an M.S. in pharmacology and toxicology from Long Island University, New York, and a B.A. in biology from Concordia College, New York..

他在纽约长岛大学获得药理学和毒理学硕士学位，并在纽约康科迪亚学院获得生物学学士学位。。

“I am very pleased to become Chairman of the Board for Meliora, a company which has the potential to make a significant clinical difference in cancer patients’ lives using its novel machine learning powered approach. I look forward to working together with David and the Meliora team to advance the company through its next stages of growth and to achieve its strategic business and pipeline objectives,” Mr.

“我很高兴成为Meliora的董事会主席，这家公司有潜力通过其新颖的机器学习方法为癌症患者的生活带来重大的临床改变。我期待着与David和Meliora团队合作，推动公司进入下一个增长阶段，并实现其战略业务和管道目标，”Mr。

Weinand commented..

韦南德评论道。。

Mr. Jean-Jacques Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals. He joined BioMarin in May 2005, when the company had a single marketed product and approximately $26 million in annual revenues.

Jean-Jacques Bienaimé先生在生物技术和制药行业拥有30多年的经验，最近担任BioMarin Pharmaceuticals的董事长兼首席执行官。他于2005年5月加入BioMarin，当时该公司只有一种上市产品，年收入约2600万美元。

Under Mr. Bienaimé's leadership, BioMarin grew significantly, from about 300 US-only employees to more than 3,400 people in almost 80 countries around the world and over $2.4 billion in sales in 2023. Biomarin received 8 drug approvals by the FDA during this time period..

。在此期间，Biomarin获得了FDA的8项药物批准。。

Before joining BioMarin, Mr. Bienaimé spent years in similar executive roles at other pharmaceutical and biotech companies and currently serves on the board of directors for Incyte, Immunome, Owkin, and Keros. Mr. Bienaimé studied economics at the École de Commerce de Paris and received an M.B.A from the University of Pennsylvania..

在加入BioMarin之前，Bienaimé先生曾在其他制药和生物技术公司担任过类似的执行职务，目前担任Incyte，Immunome，Owkin和Keros的董事会成员。。。

“I am excited to join the Meliora Board of Directors as they endeavor to bring transformative oncology therapeutics to the patients most in need through their ML-powered approach,” commented Mr. Bienaimé. “In my career, focusing on patients while leveraging the latest technology has been critical to success, and Meliora is highly aligned in this approach.

Bienaimé先生评论道：“我很高兴加入Meliora董事会，因为他们努力通过ML动力方法为最需要的患者带来变革性的肿瘤治疗方法。”。“在我的职业生涯中，在利用最新技术的同时关注患者是成功的关键，而Meliora在这种方法中高度一致。

I look forward to enhancing Meliora’s ability to execute on its compelling vision.”.

我期待着增强梅里奥拉执行其令人信服的愿景的能力。”。

About Meliora Therapeutics

关于Meliora Therapeutics

Meliora Therapeutics is discovering and developing small molecule oncology therapies for high value cancer targets with its proprietary machine learning powered platform, AnchorOmics. Pairing the first multimodal, mechanism-of-action machine learning algorithm and a world-class team of scientists and engineers, Meliora is pioneering a novel approach to create life-changing therapies for cancer patients.

Meliora Therapeutics凭借其专有的机器学习平台AnchorOmics，正在发现和开发针对高价值癌症靶标的小分子肿瘤学疗法。结合第一个多模式、作用机制机器学习算法和世界一流的科学家和工程师团队，Meliora正在开创一种新方法，为癌症患者创造改变生活的疗法。

San Francisco and Cambridge-based Meliora Therapeutics has raised $11 million to date and is led by leaders from the fields of AI, biotechnology, and drug discovery. For more information, please visit: www.melioratx.com.

总部位于旧金山和剑桥的Meliora Therapeutics迄今已筹集1100万美元，由人工智能、生物技术和药物发现领域的领导者领导。有关更多信息，请访问：www.melioratx.com。